SERVIER
Updates & Highlights
Gallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
Gallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
ArchDaily México · 1 day ago
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
MSN · 1 day ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
MSN · 1 day ago
Recent Openings
View all 1 jobsCulture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at SERVIER?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentGallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
Gallery of Servier's Center of Excellence in Clinical Research / NFOE - 16
ArchDaily México · 1 day ago
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
MSN · 1 day ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
MSN · 1 day ago
Biopharma bites: Beren readies for Niemann-Pick launch, layoffs at Teva, and more from Servier, Sensorion and Lilly
Biopharma bites: Beren readies for Niemann-Pick launch, layoffs at Teva, and more from Servier, Sensorion and Lilly
FirstWord Pharma · 2 days ago
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
Endpoints News · 2 days ago
Servier partners with n-Lorem to advance rare neurology research
Servier partners with n-Lorem to advance rare neurology research
The Pharma Letter · 2 days ago
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
PR Newswire · 2 days ago
Calmer waters for FDA; Servier , Lilly deals — a BioCentury podcast
Calmer waters for FDA; Servier , Lilly deals — a BioCentury podcast
biocentury.com · 4 days ago
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Medical Dialogues · 9 days ago
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
Oncodaily · 10 days ago
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
TradingView · 10 days ago
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
BioXconomy · 10 days ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Pharmaceutical Technology · 10 days ago
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
MedCity News · 11 days ago
Servier bets up to $2.7B for Edgewise's late-stage muscular dystrophy asset
Servier bets up to $2.7B for Edgewise's late-stage muscular dystrophy asset
FirstWord Pharma · 11 days ago
Edgewise sells muscular dystrophy assets to Servier for $2.65B
Edgewise sells muscular dystrophy assets to Servier for $2.65B
BioWorld News · 11 days ago
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
BioSpace · 11 days ago
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
pharmaphorum · 11 days ago
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Pharmaceutical Executive · 11 days ago
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
European Biotechnology Magazine · 11 days ago